Publications

Publications

The Future of NMR Metabolomics in Cancer Therapy: Towards Personalizing Treatment and Developing Targeted Drugs?

By:
Contributors: Hans Vogel Research Group
Metabolites. 2013 May 17;3(2):373-96. doi: 10.3390/metabo3020373.

Abstract

There has been a recent shift in how cancers are defined, where tumors are no longer simply classified by their tissue origin, but also by their molecular characteristics. Furthermore, personalized medicine has become a popular term and it could start to play an important role in future medical care. However, today, a “one size fits all” approach is still the most common form of cancer treatment. In this mini-review paper, we report on the role of nuclear magnetic resonance (NMR) metabolomics in drug development and in personalized medicine. NMR spectroscopy has successfully been used to evaluate current and potential therapies, both single-agents and combination therapies, to analyze toxicology, optimal dose, resistance, sensitivity, and biological mechanisms. It can also provide biological insight on tumor subtypes and their different responses to drugs, and indicate which patients are most likely to experience off-target effects and predict characteristics for treatment efficacy. Identifying pre-treatment metabolic profiles that correlate to these events could significantly improve how we view and treat tumors. We also briefly discuss several targeted cancer drugs that have been studied by metabolomics. We conclude that NMR technology provides a key platform in metabolomics that is well-positioned to play a crucial role in realizing the ultimate goal of better tailored cancer medicine.

 

PubMed

Download PDF

 

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Congratulations to top alumni honour awardee Dr. Ron Moore

Congratulations to Dr. Ron Moore, ’80 BSc, ’86 MD, ’91 PhD, who will receive an Alumni Honour Award from University of Alberta President David H. Turpin during the Alumni Awards Ceremony on Monday, Sept. 24, 2018, at the Northern Alberta Jubilee Auditorium in Edmonton.
The Alumni Honour Award recognizes the significant achievements and contributions by University of Alberta alumni to their profession and their community. Dr. Moore has made significant contributions to advancing our knowledge and treatment of bladder, kidney and prostate cancer. He has studied and developed laser treatment as therapy for prostate and bladder cancer, and developed new drugs to improve prostate cancer radiotherapy outcomes. Dr. Ron Moore has also actively mentored and trained hundreds of students throughout his career as well as serving on the APCaRI leadership committee.

The community is invited to celebrate as Dr. Ron Moore receives this top alumni award!
Date: Monday, Sept. 24, 2018
Location: Northern Alberta Jubilee Auditorium (11455 87 Ave), Edmonton, Alberta
Time: 7 p.m. ceremony with dessert reception to follow
Cost: Free, register for tickets
Dress: Business attire

For more information, please contact the Office of Alumni Relations at 780-492-3224, toll free 1-800-661-2593 or alumni@ualberta.ca
Featured at @UAlbertaAlumni and in the New Trail magazine.

- Perrin Beatty